Avidity biosciences to host investor and analyst event focused on precision cardiology candidates and first look at next-generation technology innovations on november 12, 2024

Avidity to present poster on precision cardiology candidate at american heart association (aha) scientific sessions 2024 taking place november 16-18, 2024  volume 11 of investor and analyst event series will be available via webcast november 12, 2024, at 8:00 a.m. et san diego , oct. 31, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced that the company will share new development candidates from its precision cardiology portfolio and provide a first look at its next-generation technology innovations.
RNA Ratings Summary
RNA Quant Ranking